Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Philogen SpA ( (IT:PHIL) ).
Philogen S.p.A. announced the purchase of 5,021 shares as part of its ongoing share buyback program, representing 0.0124% of the company’s share capital, for a total value of approximately Euro 94,150.81. Since the program’s inception, Philogen has acquired a total of 12,244 shares, reflecting 0.0301% of its share capital, indicating a strategic financial maneuver to potentially enhance shareholder value and market confidence.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products for treating diseases with high mortality rates. It focuses on creating targeted antitumor drugs using high-affinity ligands for tumor markers, primarily through technologies like Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries. The company’s main therapeutic strategy, tumor targeting, selectively delivers potent therapeutic agents to tumor masses while sparing healthy tissues.
YTD Price Performance: -6.05%
Average Trading Volume: 193
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €545.4M
Find detailed analytics on PHIL stock on TipRanks’ Stock Analysis page.
